Buspirone/zolmitriptan
pharmaceutical compound
Buspirone/zolmitriptan, also known by its developmental code names AV-2860 and JM-010, is a combination of buspirone, a serotonin 5-HT1A receptor partial agonist, and zolmitriptan, a serotonin 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F receptor agonist, which is under development for the treatment of drug-induced dyskinesia, specifically levodopa-induced dyskinesia in people with Parkinson's disease. It is taken orally. The drug is under development by Contera Pharma and Bukwang Pharmaceutical. As of November 2024, it is in phase 2 clinical trials for treatment of drug-induced dyskinesia. Buspirone/zolmitriptan has failed to meet its endpoints in phase 2 trials.
Begin with the source’s own compact description: “Buspirone/zolmitriptan” is pharmaceutical compound. The dossier treats that line as a proposition to test through Buspirone, zolmitriptan and pharmaceutical, not as a finished interpretation.
Why this record matters
The phrase “pharmaceutical compound” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Jul 12, 2026. The linked authority identifier is Q138023914. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2024.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Buspirone/zolmitriptan”, its source revision and the description used here.
- Expand the search: follow Buspirone/zolmitriptan primary sources, Buspirone/zolmitriptan archive and Buspirone research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Buspirone/zolmitriptan”?
- Which institution is responsible for the underlying evidence?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Buspirone/zolmitriptan” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.